Browsing Category
Healthcare Newsdesk
304 posts
AviadoBioTM Raises $80 million in Series A Financing to Advance Neurodegenerative Gene Therapy Platform
AviadoBioTM Raises $80 million in Series A Financing to Advance Neurodegenerative Gene Therapy Platform Series A led by…
Small Pharma to Participate in the H.C. Wainwright 2nd Annual Psychedelics Virtual Conference on December 6, 2021
LONDON, Dec. 01, 2021 (GLOBE NEWSWIRE) — Small Pharma Inc. (TSXV: DMT) (OTCQB: DMTTF) (the “Company” or “Small…
Silence Therapeutics Welcomes Deep Track Capital as New Shareholder
1 December 2021 LONDON, Silence Therapeutics plc, Nasdaq: SLN (“Silence” or “the Company”), a leader in the discovery,…
COMPASS Pathways announces further positive results from groundbreaking phase IIb trial of investigational COMP360 psilocybin therapy for treatment-resistant depression
– Positive topline results validated by additional analyses – Patient improvements beyond reduction of depression symptoms – Further…
OKYO Pharma Limited: Directorate Change
LONDON, Dec. 01, 2021 (GLOBE NEWSWIRE) — OKYO Pharma Limited (“OKYO” or the “Company”) today announces that Bernard…
First Evidence of High-Dose Methotrexate Related Toxicity in Spain Presented at Virtual ISPOR Europe 2021
COPENHAGEN, Denmark, Dec. 01, 2021 (GLOBE NEWSWIRE) — The first evidence of high dose methotrexate related toxicity (HDMTX)…
Emergex confirms its next generation T-Cell Priming COVID-19 vaccine candidate has the potential to be effective against all currently sequenced viral mutations
PRESS RELEASE Emergex confirms its next generation T–Cell Priming COVID-19 vaccine candidate has the potential to be effective…
COMPASS Pathways to participate in upcoming Evercore, H.C. Wainwright & Berenberg investor conferences
LONDON, Nov. 30, 2021 (GLOBE NEWSWIRE) — COMPASS Pathways plc (Nasdaq: CMPS), a mental health care company dedicated…
Silence Therapeutics Begins Exclusive Nasdaq Trading
Silence Therapeutics Begins Exclusive Nasdaq Trading 30 November 2021 LONDON, Silence Therapeutics plc, Nasdaq:SLN (“Silence” or “the Company“),…
Mereo BioPharma Reports Interim Data from ACTIVATE Phase 1b/2 Open Label Study of etigilimab Anti-TIGIT Antibody in combination with Nivolumab in Solid Tumors
One complete response, one partial response and four cases of stable disease observed among 15 patients in the…
